Wyeth's Xyntha gets FDA OK

02/21/2008 | MarketWatch

The FDA on Thursday announced that it has cleared Wyeth's drug Xyntha as treatment for rare blood-clotting disorder hemophilia A. The drug is indicated for regulating and preventing spontaneous or post-injury bleeding in patients with the disorder.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX